Vantictumab, formerly identified as OMP18R5, represents the novel monoclonal body designed with specifically block OPN receptor 18R5. click here The approach is actively studied by researchers regarding potential treatments in several orthopedic diseases, particularly situations involving excessive bone breakdown. Preclinical data suggest Vantictum